search
Back to results

FUNctional eFficacy of Hybrid coronAry REvascularization (FUNFARE)

Primary Purpose

Coronary Artery Disease

Status
Terminated
Phase
Not Applicable
Locations
Russian Federation
Study Type
Interventional
Intervention
Hybrid coronary revascularization
Coronary artery bypass grafting
Sponsored by
Tomsk National Research Medical Center of the Russian Academy of Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Disease focused on measuring Myocardial Revascularization, Coronary Artery Bypass, Internal Mammary-Coronary Artery Anastomosis, Drug-Eluting Stents

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Signed written informed consent
  • Stenosis ≥70% of the LAD and/or ≥50% of left main coronary artery in combination with at least one stenosis ≥70% of the Cx or RCA, suitable for revascularization (decided by a heart team)
  • SYNTAX value ≥22.
  • Clinical indications for coronary revascularization (angina refractory to optimal medical treatment, ischemia on non-invasive tests, reduced left ventricular ejection fraction)

Exclusion Criteria:

  • Previous heart surgery of any kind, including CABG
  • Previous surgery involving the left pleural space
  • The need for concomitant vascular or other cardiac surgery during index procedure (valve surgery, aortic surgery, left ventricular aneurysmectomy, endarterectomy, etc.)
  • Chronic lung disease
  • Chronic kidney disease determined as eGFR<60 ml/min/sq.m
  • Failure to give informed consent.
  • Life expectancy due to non-heart disease is less than 1 year.

Sites / Locations

  • Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Hybrid coronary revascularization (HCR)

Conventional coronary artery bypass grafting (CABG)

Arm Description

Patients with multi-vessel CAD randomized to hybrid coronary revascularization

Patients with multi-vessel CAD randomized to conventional CABG

Outcomes

Primary Outcome Measures

Functional efficacy of revascularization
Will be assessed as weighted average of the residual (12 month post-procedure) iFRs in coronary arteries that had at least one significant stenosis (>70% for CABG group, iFR ≤ 0.89 for iFR-guided HCR) and diameter ≥1.5 mm at baseline. In case of proximal lesions of LAD, Cx, RCA, the coefficients 0.5; 0.25; 0.25 will be used, respectively. For other lesions Duke jeopardy scores will be used instead (for this scoring, the coronary tree is divided into 6 segments:1) LAD beyond the diagonal branch take-off, 2) major diagonal branch of the LAD, 3) major septal branch of the LAD, 4) Cx beyond the major obtuse margin branch take-off, 5) major obtuse margin branch, and 6) the posterior descending branch of the RCA. Each such segment is assigned 2 points with a possible maximum of 12/12.

Secondary Outcome Measures

Between-group difference in the number of major cardiovascular and cerebral events (MACCE)
The components of MACCE will be all-cause mortality, myocardial infarction (MI), stroke, and unplanned coronary revascularization
Between-group difference in the functional efficacy of the revascularization of non-LAD arteries
Will be assessed as weighted average of the residual (12 month post-procedure) iFRs in all non-LAD coronary arteries with at least one significant stenosis (>70% for CABG group, iFR ≤ 0.89 for iFR-guided HCR) and diameter ≥1.5 mm at baseline
Between-group difference in the functional completeness of the revascularization
The functional completeness will be assessed as the proportion of the coronary arteries with significant iFR at12 month post-procedure among the arteries with at least one significant stenosis (>70% for CABG group, iFR ≤ 0.89 for iFR-guided HCR) and diameter ≥1.5 mm at baseline
Between-group difference in the number of serious adverse events (other than MACCE)
Any untoward medical occurrence that is life-threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity
Between-group difference in the frequency of serious adverse events in the peri-operative period
Any untoward medical occurrence that is life-threatening, requires prolongation of existing hospitalization, results in persistent or significant disability/incapacity. For HCR - a combination of the events during both surgical and endovascular stages (including stent thrombosis, dissections/ perforations/ruptures of coronary arteries, contrast nephropathy, pseudoaneurysms requiring surgical treatment)
Between-group difference in the operation duration
Duration of the operation in minutes
Between-group difference in the mechanical ventilation time
A total inspiratory time when the tidal volume was delivered or the pressure was maintained
Between-group difference in ICU stay
A total time spent in intensive care unit in hours
Between-group difference in the number of patients who undergone re-operation for bleeding
Repeat surgery needed for bleeding or cardiac tamponade either before hospital discharge or between hospital discharge and within 30 days of their index operation if discharged earlier than 30 days
Between-group difference in the number of patients who received blood transfusion(s)
Any transfusion of blood or blood products
Between-group difference in the number of patients with wound infection
Purulent discharge from the surgical site, wound or drain placed in the wound with at least one of the following signs/symptoms - pain or tenderness, localised swelling, or redness/heat
Between-group difference in hospital stay
A total number of days spent in hospital after surgery including PCI stage
Between-group difference in the number of repeated revascularizations
Any surgical or endovascular revascularization
Between-group difference in the number of hospitalizations
Any hospital stay longer than 24 hours
Between-group difference in angina score
Canadian Cardiovascular Society Classification
Between-group difference in the quality of life
Will be assessed using EQ-5D instrument
Effect of proportion of coronary arteries with significant iFR 12 month post-procedure among the arteries with ≥1 significant stenosis and diameter ≥1.5 mm at baseline on probability of MACCE in patients with anatomically complete procedures
Effect of functional completeness of revascularization on occurrence of MACCE evaluated by logistic regression model

Full Information

First Posted
December 4, 2020
Last Updated
May 4, 2023
Sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences
search

1. Study Identification

Unique Protocol Identification Number
NCT04698460
Brief Title
FUNctional eFficacy of Hybrid coronAry REvascularization
Acronym
FUNFARE
Official Title
Functional Efficacy of iFR-guided Hybrid Coronary Revascularization vs Conventional Coronary Artery Bypass Grafting: a Randomized Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Terminated
Why Stopped
The local research project is cancelled because of the organizational issues
Study Start Date
January 15, 2021 (Actual)
Primary Completion Date
May 5, 2023 (Actual)
Study Completion Date
May 5, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the study is to compare iFR-guided hybrid coronary revascularization (HCR) and traditional coronary artery bypass grafting (CABG) in terms of a functional efficacy of revascularization assessed by weighted average of iFRs measured 12 month post-procedure in the qualified coronary arteries (all arteries with at least one significant lesion and diameter >1.5 mm at baseline). The true significance of coronary artery disease (CAD) is reflected by the pressure gradients in coronary arteries showing the actual drop in myocardial perfusion whereas the degree of anatomical narrowing in fact only indicates a potential for hemodynamical changes that also depend on vessel compliance, distal vascular resistance, and collateral circulation. Then, the true effect of myocardial revascularization as treatment of CAD should be likewise assessed by measuring residual pressure gradients in coronary arteries remaining after revascularization, i.e. as the functional efficacy in analogy to the functional significance of CAD.
Detailed Description
New generation of drug eluting stents (DES) have been shown to have better long-term patency rates than the vein grafts utilized in conventional CABG. Then, it may be expected that hybrid coronary revascularization (HCR) combining minimally invasive direct coronary artery bypass (MIDCAB) grafting of left anterior descending (LAD) artery by left internal mammary artery (LIMA) and stenting of non-LAD coronary arteries with the new generation DESs may have superior efficacy and safety compared to conventional CABG in patients with multivessel coronary artery disease (CAD). The true significance of CAD is reflected by the pressure gradients in coronary arteries that show actual changes in coronary blood flow and myocardial perfusion whereas the degree of anatomical narrowing only indicates a potential for the hemodynamical changes that also depend on vessel compliance, distal vascular resistance, and collateral circulation. Then, the true effect of myocardial revascularization as treatment of CAD should be likewise assessed by measuring residual pressure gradients in coronary arteries after revascularization, i.e. as the functional efficacy in analogy to the functional significance of CAD. For multi-vessel disease the summary hemodynamic effectiveness of revascularization may be captured either by continuous variable, e.g. averaged magnitude of the post-procedural pressure gradients in the qualified arteries or by categorical index, e.g. a relative proportion of the arteries with significant post-procedural pressure gradients among the qualified arteries both preferably weighted for their significance in myocardial blood supply. For comprehensive comparison of the revascularization strategies the qualified arteries should include all arteries/branches that had significant disease at baseline and were amenable to treatment with at least one of the revascularization methods, e.g. with at least one stenosis >70% and diameter >1.5 mm. The categorical measure of the functional efficacy may also be considered a measure of the functional completeness of revascularization in analogy to the conventional anatomical completeness. This functional completeness in terms of removal of all significant pressure gradients in coronary arteries is expected to be superior to anatomical completeness for assessing the procedural success of the intervention because the successful grafting/stent implantation does not guarantee the permanent removal of the pressure gradients, which may still persist due to development of intimal hyperplasia along the suture line of surgical anastomosis or stent underexpansion/edge dissection. The primary purpose of the study is to assess whether iFR -guided HCR done as the staged procedure with LIMA-LAD MIDCAB at first stage, and percutaneous coronary intervention (PCI) of non-LAD arteries at the second stage, is superior to conventional CABG in terms of the functional efficacy of revascularization assessed by the weighted average of iFRs measured 12 month post-procedure in all coronary arteries with at least one significant stenosis (>70% for CABG group, iFR ≤ 0.89 for iFR-guided HCR) and diameter ≥1.5 mm at baseline. For proximal lesions in major coronary arteries - LAD, circumflex (Cx), and right coronary artery (RCA) - the simple weights 0.5, 0.25, 0.25 will be used, respectively. For other lesions the Duke jeopardy scores will be used instead. Measurement of functional efficacy at 12 month post-procedure will allow assessment of the final result of the intervention after complete vessel healing, endothelialization of the stents, on stable antithrombotic treatment, etc. Also, this study will assess whether achieving the functional completeness of revascularization described above in addition to the anatomical completeness of the procedure may further improve the treatment outcomes in patients with multivessel CAD. Specifically, the investigators will assess the relationship between the functional completeness of the revascularization and the occurrence of the MACCE over 1, 3, and 5 years following randomization in the patients with anatomically complete procedures. Finally, the hypothesis will be tested that iFR-guided HCR has better overall safety than CABG. Whereas, compared to CABG HCR is associated with less frequent perioperative complications, blood transfusions, shorter ICU and hospital stays, these benefits of less invasive treatment may be overridden by the additional complications of stenting, e.g. acute stent thrombosis, dissection, arterial perforation/rupture and others. With iFR guidance of the HCR these additional complications of PCI are expected to be less frequent and the whole procedure - more safe.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease
Keywords
Myocardial Revascularization, Coronary Artery Bypass, Internal Mammary-Coronary Artery Anastomosis, Drug-Eluting Stents

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
13 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Hybrid coronary revascularization (HCR)
Arm Type
Experimental
Arm Description
Patients with multi-vessel CAD randomized to hybrid coronary revascularization
Arm Title
Conventional coronary artery bypass grafting (CABG)
Arm Type
Active Comparator
Arm Description
Patients with multi-vessel CAD randomized to conventional CABG
Intervention Type
Procedure
Intervention Name(s)
Hybrid coronary revascularization
Intervention Description
A staged procedure with a minimally invasive direct coronary artery bypass grafting of left anterior descending artery by left internal mammary artery (LIMA-LAD MIDCAB) at first stage, and percutaneous stenting of iFR-significant lesions in non-LAD arteries at the second stage
Intervention Type
Procedure
Intervention Name(s)
Coronary artery bypass grafting
Intervention Description
A conventional procedure of median thoracotomy with on-pump bypass grafting of left anterior descending artery by left internal mammary artery and saphenous vein grafting of circumflex and/or right coronary artery
Primary Outcome Measure Information:
Title
Functional efficacy of revascularization
Description
Will be assessed as weighted average of the residual (12 month post-procedure) iFRs in coronary arteries that had at least one significant stenosis (>70% for CABG group, iFR ≤ 0.89 for iFR-guided HCR) and diameter ≥1.5 mm at baseline. In case of proximal lesions of LAD, Cx, RCA, the coefficients 0.5; 0.25; 0.25 will be used, respectively. For other lesions Duke jeopardy scores will be used instead (for this scoring, the coronary tree is divided into 6 segments:1) LAD beyond the diagonal branch take-off, 2) major diagonal branch of the LAD, 3) major septal branch of the LAD, 4) Cx beyond the major obtuse margin branch take-off, 5) major obtuse margin branch, and 6) the posterior descending branch of the RCA. Each such segment is assigned 2 points with a possible maximum of 12/12.
Time Frame
From baseline to 12 month
Secondary Outcome Measure Information:
Title
Between-group difference in the number of major cardiovascular and cerebral events (MACCE)
Description
The components of MACCE will be all-cause mortality, myocardial infarction (MI), stroke, and unplanned coronary revascularization
Time Frame
From baseline to 12 months, 3, and 5 years
Title
Between-group difference in the functional efficacy of the revascularization of non-LAD arteries
Description
Will be assessed as weighted average of the residual (12 month post-procedure) iFRs in all non-LAD coronary arteries with at least one significant stenosis (>70% for CABG group, iFR ≤ 0.89 for iFR-guided HCR) and diameter ≥1.5 mm at baseline
Time Frame
From baseline to 12 months
Title
Between-group difference in the functional completeness of the revascularization
Description
The functional completeness will be assessed as the proportion of the coronary arteries with significant iFR at12 month post-procedure among the arteries with at least one significant stenosis (>70% for CABG group, iFR ≤ 0.89 for iFR-guided HCR) and diameter ≥1.5 mm at baseline
Time Frame
From baseline to 12 months
Title
Between-group difference in the number of serious adverse events (other than MACCE)
Description
Any untoward medical occurrence that is life-threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity
Time Frame
From baseline to 12 months
Title
Between-group difference in the frequency of serious adverse events in the peri-operative period
Description
Any untoward medical occurrence that is life-threatening, requires prolongation of existing hospitalization, results in persistent or significant disability/incapacity. For HCR - a combination of the events during both surgical and endovascular stages (including stent thrombosis, dissections/ perforations/ruptures of coronary arteries, contrast nephropathy, pseudoaneurysms requiring surgical treatment)
Time Frame
From the day of procedure to one week post-procedure
Title
Between-group difference in the operation duration
Description
Duration of the operation in minutes
Time Frame
From the time of intubation to the time of discharge from operating room assessed up to 24 hours
Title
Between-group difference in the mechanical ventilation time
Description
A total inspiratory time when the tidal volume was delivered or the pressure was maintained
Time Frame
From the intubation to complete withdrawal of ventilation support assessed up to 1 week
Title
Between-group difference in ICU stay
Description
A total time spent in intensive care unit in hours
Time Frame
From the time of discharge from operating room to the time of discharge from ICU assessed up to 30 days
Title
Between-group difference in the number of patients who undergone re-operation for bleeding
Description
Repeat surgery needed for bleeding or cardiac tamponade either before hospital discharge or between hospital discharge and within 30 days of their index operation if discharged earlier than 30 days
Time Frame
From the index operation to 30 days post-procedure
Title
Between-group difference in the number of patients who received blood transfusion(s)
Description
Any transfusion of blood or blood products
Time Frame
From the day of CABG to hospital discharge assessed up to 30 days
Title
Between-group difference in the number of patients with wound infection
Description
Purulent discharge from the surgical site, wound or drain placed in the wound with at least one of the following signs/symptoms - pain or tenderness, localised swelling, or redness/heat
Time Frame
From the end of surgery to hospital discharge assessed up to 30 days
Title
Between-group difference in hospital stay
Description
A total number of days spent in hospital after surgery including PCI stage
Time Frame
From the day of CABG to the discharge after PCI assessed up to 2 months
Title
Between-group difference in the number of repeated revascularizations
Description
Any surgical or endovascular revascularization
Time Frame
From baseline to 12 months
Title
Between-group difference in the number of hospitalizations
Description
Any hospital stay longer than 24 hours
Time Frame
From baseline to 12 months follow-up
Title
Between-group difference in angina score
Description
Canadian Cardiovascular Society Classification
Time Frame
12 months after the procedure
Title
Between-group difference in the quality of life
Description
Will be assessed using EQ-5D instrument
Time Frame
12 months after the procedure
Title
Effect of proportion of coronary arteries with significant iFR 12 month post-procedure among the arteries with ≥1 significant stenosis and diameter ≥1.5 mm at baseline on probability of MACCE in patients with anatomically complete procedures
Description
Effect of functional completeness of revascularization on occurrence of MACCE evaluated by logistic regression model
Time Frame
1, 3, and 5 years following randomization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed written informed consent Stenosis ≥70% of the LAD and/or ≥50% of left main coronary artery in combination with at least one stenosis ≥70% of the Cx or RCA, suitable for revascularization (decided by a heart team) SYNTAX value ≥22. Clinical indications for coronary revascularization (angina refractory to optimal medical treatment, ischemia on non-invasive tests, reduced left ventricular ejection fraction) Exclusion Criteria: Previous heart surgery of any kind, including CABG Previous surgery involving the left pleural space The need for concomitant vascular or other cardiac surgery during index procedure (valve surgery, aortic surgery, left ventricular aneurysmectomy, endarterectomy, etc.) Chronic lung disease Chronic kidney disease determined as eGFR<60 ml/min/sq.m Failure to give informed consent. Life expectancy due to non-heart disease is less than 1 year.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stanislav Pekarskiy
Organizational Affiliation
Cardiology Research Institute, TNRMC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Yuri Vecherskiy
Organizational Affiliation
Cardiology Research Institute, TNRMC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Boris Kozlov
Organizational Affiliation
Cardiology Research Institute, TNRMC
Official's Role
Study Director
Facility Information:
Facility Name
Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences
City
Tomsk
State/Province
Tomsk Oblast
ZIP/Postal Code
634012
Country
Russian Federation

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

FUNctional eFficacy of Hybrid coronAry REvascularization

We'll reach out to this number within 24 hrs